Endoscopic hemostasis with a self-expandable metal stent as bridge therapy for hemobilia
Endoscopy International Open · 29.01.2025 · 13 (CP)
DOI: 10.1055/a-2480-7065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy International Open, erschienen am 29.01.2025. Verfasst von Junyeol Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Jongno-gu, Korea (the Republic of). Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Management of hemobilia is often challenging. Recently, endoscopic hemostasis with a self-expandable metal stent (SEMS) has shown promising efficacy for controlling bleeding at the endoscopic sphincterotomy site. This study aimed to assess efficacy and feasibility of endoscopic hemostasis as bridge therapy for hemobilia. Patients with hemobilia between 2008 and 2023 were retrospectively reviewed. We compared efficacy of hemostasis between the initial endoscopic hemostasis group (ENDO group) and the initial angiographic embolization group (EMBO group). The primary outcome was initial hemostasis success rate and the secondary outcomes were delayed bleeding rate, subsequent embolization rate, 28-day mortality, transfusion amount, time to first hemostasis, total hemobilia time, and incidence of hypovolemic shock. A total of 26 patients with hemobilia were included in this study and 17 patients (65.4%) were identified as the ENDO group and nine patients (34.6%) were classified as the EMBO group. The success rate of initial hemostasis was 88.2% (15/17) in the ENDO group and 100% (9/9) in the EMBO group (P = 0.529). The rate of delayed bleeding in the ENDO group was 17.6% (3/17) and 0.0% (0/9) in the EMBO group (P = 0.529). Total hemobilia time was shorter in the ENDO group than in the EMBO group (mean: 281.5 ± 1022.4 minutes vs. 5002.8 ± 7982.6 minutes; P < 0.001) Stent insertion depth was associated with successful hemostasis without delayed bleeding. (P = 0.015). Endoscopic hemostasis using SEMS for hemobilia appeared to be a feasible bridge therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Jongno-gu, Korea (the Republic of).
- Division of Gastroenterology, Chung-Ang University College of Medicine, Seoul, Korea (the Republic of).
ORCID-Profile: Sang Hyub Lee
Zitieren
APA
Kim, J., Choi, J. H., Lee, T. S., Lee, M. H., Cho, I. R., Paik, W. H., Ryu, J. K., Kim, Y. T., & Lee, S. H. (2025). Endoscopic hemostasis with a self-expandable metal stent as bridge therapy for hemobilia. Endoscopy International Open, 13(CP). https://doi.org/10.1055/a-2480-7065
Vancouver
Kim J, Choi JH, Lee TS, Lee MH, Cho IR, Paik WH, et al. Endoscopic hemostasis with a self-expandable metal stent as bridge therapy for hemobilia. Endoscopy International Open. 2025;13(CP). doi:10.1055/a-2480-7065
BibTeX
@article{Kim2025,
author = {Kim, Junyeol and Choi, Jin Ho and Lee, Tae Seung and Lee, Myeong Hwan and Cho, In Rae and Paik, Woo Hyun and Ryu, Ji Kon and Kim, Yong-Tae and Lee, Sang Hyub},
title = {Endoscopic hemostasis with a self-expandable metal stent as bridge therapy for hemobilia},
journal = {Endoscopy International Open},
year = {2025},
volume = {13},
number = {CP},
doi = {10.1055/a-2480-7065}
}
EUVIMED